The buying spree yesterday was over in an instant (there was one approximately 2500 contract buy / fill at .35 that skipped over my sale order), and the one today didn't last much longer (I sold 100 contracts to the big-timer at $.45). They're running out of time to fully cover, but it is heartening that is what seems to be taking place. On our previous data releases, it seemed like big money knew exactly when they would strike and what the effect would be. They also ran the price up beforehand (basically triple in the month before CTAD 2015 and basically double in the month before AAIC 2016.) Here, someone is spending $200,000+ (I'd say average price was $.37 or more, whereas smaller volumes of Nov7.5 could be easily had for .20 on Monday or Tuesday morning), because they are legitimately concerned their short interests will be in trouble. This "run-up" has been plodding, and given what other recent bios have done with good data releases (MCRB, SRRK, etc), AVXL could really take off and with the likely interest will be much much harder to control. Plus, with Rett results hanging overhead (and I'd be willing to wager they have them now or within a week or 2), folks probably don't want to risk their huge sums of money on 2 double-blind trials that could demonstrate MOA. They knew back in 2015 / 2016 they could shock and awe ignorant retail interests, by hiring a couple of hack journalists, running misdirection and repeating the "warning" that it wasn't a double-blind, placebo-controlled study, and by inference was worthless.
Anyone know the cost to borrow shares? For CTAD 2015 and AAIC 2016, the demand / cost to borrow shares was pretty high, and there weren't that many available. The cascading waterfall of shorts flooding the market a few seconds before the data was released for AAIC 2016 is something I'll not soon forget.
News 
Market Data 
Discover 
